<DOC>
	<DOCNO>NCT02824952</DOCNO>
	<brief_summary>Patients receive AZD9291 dose 80 mg daily . Systemic evaluation do PET-CT scan 6 week . In respond patient AZD9291 give orally 80 mg daily 12 week . Non-responding patient receive AZD9291 period 6 12 week ( accord result response assessment time-point ) .</brief_summary>
	<brief_title>Neo-adjuvant Trial With AZD9291 EGFRm+ Stage IIIA/B NSCLC</brief_title>
	<detailed_description>Patients receive AZD9291 dose 80 mg daily . Systemic evaluation do PET-CT scan 6 week . In respond patient AZD9291 give orally 80 mg daily 12 week . Non-responding patient receive AZD9291 period 6 12 week ( accord result response assessment time-point ) . All patient follow 2 year . The imaging modality use RECIST v1.1 assessment PET-CT scan .</detailed_description>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Male female , age least 18 year . 3 . Treatmentnaïve stage IIIA/B NSCLC activate sensitize EGFR mutation/T790M • Uncommon sensitize EGFR mutation allow . 4 . Measurable disease RECIST criterion v1.1 . 5 . Patients amenable curative chemoradiotherapy . 6 . ECOG PS 0/1 . 7 . Normal hematologic , renal liver function : Absolute neutrophil count &gt; 1500/mm3 , platelet &gt; 100,000/mm3 , hemoglobin &gt; 9 g/dL ; Creatinine concentration &lt; 1 mg/dL , creatinine clearance &gt; 60 mL/min ; Total bilirubin = &lt; 1.5 mg/dL , ALT+ AST level = &lt; 3 time upper normal limit . 8 . FEV1 &gt; 1 liter . 9 . Female patient reproductive potential must negative pregnancy test ( serum/urine ) prior start treatment . 10 . All patient reproductive potential must agree use barrier contraception method receive study treatment . 1 . EGFR TKI resistant EGFR mutation ( e.g. , insertion exon 20 ) • T790M allow . 2 . Treatment follow : 1 . Prior treatment systemic anticancer therapy advance NSCLC ; 2 . Prior treatment EGFRTKI ; 3 . Major surgery within 4 week first dose study drug ; 4 . Treatment investigational drug within five halflives compound . 3 . Pregnant lactating woman . 4 . Inability sign inform consent form . 5 . Any concurrent and/or active malignancy require systemic treatment within 2 year first dose study drug . 6 . Any evidence severe uncontrolled systemic disease , include uncontrolled hypertension active bleeding diatheses ; active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , uncontrolled diabetes . 7 . Inability swallow formulate product , malabsorption syndrome , refractory nausea vomit would preclude adequate absorption AZD9291 . 8 . Any following cardiac criterion : Mean rest correct QT interval ( QTc ) &gt; 470 msec , obtain 3 consequent ECGs , use screen clinic ECG machinederived QTc value ; Any clinically important abnormality rhythm , conduction , morphology rest ECG ; Any factor increase risk QTc prolongation risk arrhythmic event , include unexplained sudden death 40 year age firstdegree relative , concomitant medication know prolong QTc interval . 9 . Any evidence/past medical history interstitial lung disease ( ILD ) radiation pneumonitis require steroid treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Tagrisso</keyword>
	<keyword>AZD9291</keyword>
	<keyword>EGFRm</keyword>
	<keyword>NSCLC</keyword>
</DOC>